| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.768 | 0.004 | 0.768 | 5 Hydroxytryptamine release stimulant | 0.768 0.004 DBMET03256 0.768 0.004 DBMET03257 | ||
| 0.686 | 0.009 | 0.686 | Aldehyde oxidase inhibitor | 0.686 0.009 DBMET03256 0.686 0.009 DBMET03257 | ||
| 0.654 | 0.003 | 0.654 | Alpha-N-acetylglucosaminidase inhibitor | 0.654 0.003 DBMET03256 0.654 0.003 DBMET03257 | ||
| 0.541 | 0.019 | 0.541 | Spasmolytic | 0.541 0.019 DBMET03256 0.541 0.019 DBMET03257 | ||
| 0.529 | 0.024 | 0.529 | 5 Hydroxytryptamine release inhibitor | 0.529 0.024 DBMET03256 0.529 0.024 DBMET03257 | ||
| 0.49 | 0.012 | 0.49 | Psychostimulant | 0.49 0.012 DBMET03256 0.49 0.012 DBMET03257 | ||
| 0.484 | 0.014 | 0.484 | Superoxide dismutase inhibitor | 0.484 0.014 DBMET03256 0.484 0.014 DBMET03257 | ||
| 0.466 | 0.004 | 0.466 | Tyrosine 3 hydroxylase inhibitor | 0.466 0.004 DBMET03256 0.466 0.004 DBMET03257 | ||
| 0.516 | 0.054 | 0.516 | Caspase 9 stimulant | 0.516 0.054 DBMET03256 0.516 0.054 DBMET03257 | ||
| 0.485 | 0.025 | 0.485 | Immunomodulator | 0.485 0.025 DBMET03256 0.485 0.025 DBMET03257 | ||
| 0.444 | 0.018 | 0.444 | DNA synthesis inhibitor | 0.444 0.018 DBMET03256 0.444 0.018 DBMET03257 | ||
| 0.463 | 0.037 | 0.463 | Vasodilator, peripheral | 0.463 0.037 DBMET03256 0.463 0.037 DBMET03257 | ||
| 0.433 | 0.009 | 0.433 | 5 Hydroxytryptamine uptake stimulant | 0.433 0.009 DBMET03256 0.433 0.009 DBMET03257 | ||
| 0.429 | 0.008 | 0.429 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.429 0.008 DBMET03256 0.429 0.008 DBMET03257 | ||
| 0.449 | 0.037 | 0.449 | Immunostimulant | 0.449 0.037 DBMET03256 0.449 0.037 DBMET03257 | ||
| 0.447 | 0.043 | 0.447 | GABA C receptor rho-3 antagonist | 0.447 0.043 DBMET03256 0.447 0.043 DBMET03257 | ||
| 0.414 | 0.019 | 0.414 | Peroxidase inhibitor | 0.414 0.019 DBMET03256 0.414 0.019 DBMET03257 | ||
| 0.39 | 0.008 | 0.39 | Peptidyltransferase inhibitor | 0.39 0.008 DBMET03256 0.39 0.008 DBMET03257 | ||
| 0.388 | 0.011 | 0.388 | Phospholipase C inhibitor | 0.388 0.011 DBMET03256 0.388 0.011 DBMET03257 | ||
| 0.403 | 0.034 | 0.403 | Vasodilator, coronary | 0.403 0.034 DBMET03256 0.403 0.034 DBMET03257 | ||
| 0.382 | 0.023 | 0.382 | Sodium/bile acid cotransporter inhibitor | 0.382 0.023 DBMET03256 0.382 0.023 DBMET03257 | ||
| 0.411 | 0.07 | 0.411 | Histamine release inhibitor | 0.411 0.07 DBMET03256 0.411 0.07 DBMET03257 | ||
| 0.391 | 0.051 | 0.391 | Cholesterol antagonist | 0.391 0.051 DBMET03256 0.391 0.051 DBMET03257 | ||
| 0.32 | 0.004 | 0.32 | Ornithine carbamoyltransferase inhibitor | 0.32 0.004 DBMET03256 0.32 0.004 DBMET03257 | ||
| 0.346 | 0.034 | 0.346 | Angiogenesis stimulant | 0.346 0.034 DBMET03256 0.346 0.034 DBMET03257 | ||
| 0.343 | 0.035 | 0.343 | Vasodilator | 0.343 0.035 DBMET03256 0.343 0.035 DBMET03257 | ||
| 0.345 | 0.04 | 0.345 | Cardiotonic | 0.345 0.04 DBMET03256 0.345 0.04 DBMET03257 | ||
| 0.309 | 0.012 | 0.309 | Anesthetic local | 0.309 0.012 DBMET03256 0.309 0.012 DBMET03257 | ||
| 0.355 | 0.063 | 0.355 | Antithrombotic | 0.355 0.063 DBMET03256 0.355 0.063 DBMET03257 | ||
| 0.293 | 0.01 | 0.293 | GABA C receptor agonist | 0.293 0.01 DBMET03256 0.293 0.01 DBMET03257 | ||
| 0.287 | 0.013 | 0.287 | Succinate dehydrogenase inhibitor | 0.287 0.013 DBMET03256 0.287 0.013 DBMET03257 | ||
| 0.329 | 0.056 | 0.329 | Interleukin 2 agonist | 0.329 0.056 DBMET03256 0.329 0.056 DBMET03257 | ||
| 0.351 | 0.086 | 0.351 | Calpain 2 inhibitor | 0.351 0.086 DBMET03256 0.351 0.086 DBMET03257 | ||
| 0.277 | 0.012 | 0.277 | Cell wall synthesis inhibitor | 0.277 0.012 DBMET03256 0.277 0.012 DBMET03257 | ||
| 0.357 | 0.098 | 0.357 | Antibacterial | 0.357 0.098 DBMET03256 0.357 0.098 DBMET03257 | ||
| 0.303 | 0.047 | 0.303 | Interleukin agonist | 0.303 0.047 DBMET03256 0.303 0.047 DBMET03257 | ||
| 0.289 | 0.034 | 0.289 | Growth hormone agonist | 0.289 0.034 DBMET03256 0.289 0.034 DBMET03257 | ||
| 0.251 | 0.004 | 0.251 | Sphingomyelinase inhibitor | 0.251 0.004 DBMET03256 0.251 0.004 DBMET03257 | ||
| 0.287 | 0.043 | 0.287 | Gastrin inhibitor | 0.287 0.043 DBMET03256 0.287 0.043 DBMET03257 | ||
| 0.242 | 0.004 | 0.242 | Adenylate cyclase stimulant | 0.242 0.004 DBMET03256 0.242 0.004 DBMET03257 | ||
| 0.33 | 0.093 | 0.33 | Toll-Like receptor agonist | 0.33 0.093 DBMET03256 0.33 0.093 DBMET03257 | ||
| 0.278 | 0.043 | 0.278 | Calpain inhibitor | 0.278 0.043 DBMET03256 0.278 0.043 DBMET03257 | ||
| 0.295 | 0.062 | 0.295 | Insulysin inhibitor | 0.295 0.062 DBMET03256 0.295 0.062 DBMET03257 | ||
| 0.232 | 0.005 | 0.232 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.232 0.005 DBMET03256 0.232 0.005 DBMET03257 | ||
| 0.232 | 0.01 | 0.232 | Catalase inhibitor | 0.232 0.01 DBMET03256 0.232 0.01 DBMET03257 | ||
| 0.321 | 0.103 | 0.321 | Antiobesity | 0.321 0.103 DBMET03256 0.321 0.103 DBMET03257 | ||
| 0.25 | 0.033 | 0.25 | Thrombolytic | 0.25 0.033 DBMET03256 0.25 0.033 DBMET03257 | ||
| 0.22 | 0.005 | 0.22 | CDC-like kinase 3 inhibitor | 0.22 0.005 DBMET03256 0.22 0.005 DBMET03257 | ||
| 0.26 | 0.047 | 0.26 | Neuropeptide Y2 antagonist | 0.26 0.047 DBMET03256 0.26 0.047 DBMET03257 | ||
| 0.259 | 0.047 | 0.259 | Anesthetic general | 0.259 0.047 DBMET03256 0.259 0.047 DBMET03257 | ||
| 0.249 | 0.039 | 0.249 | Anticoagulant | 0.249 0.039 DBMET03256 0.249 0.039 DBMET03257 | ||
| 0.224 | 0.015 | 0.224 | Toll-Like receptor 2 antagonist | 0.224 0.015 DBMET03256 0.224 0.015 DBMET03257 | ||
| 0.213 | 0.01 | 0.213 | GABA C receptor antagonist | 0.213 0.01 DBMET03256 0.213 0.01 DBMET03257 | ||
| 0.204 | 0.006 | 0.204 | Alcohol oxidase inhibitor | 0.204 0.006 DBMET03256 0.204 0.006 DBMET03257 | ||
| 0.204 | 0.006 | 0.204 | Adrenaline agonist | 0.204 0.006 DBMET03256 0.204 0.006 DBMET03257 | ||
| 0.215 | 0.02 | 0.215 | MAP kinase 9 inhibitor | 0.215 0.02 DBMET03256 0.215 0.02 DBMET03257 | ||
| 0.243 | 0.048 | 0.243 | CDC-like kinase 2 inhibitor | 0.243 0.048 DBMET03256 0.243 0.048 DBMET03257 | ||
| 0.225 | 0.031 | 0.225 | Phospholipase A2 inhibitor | 0.225 0.031 DBMET03256 0.225 0.031 DBMET03257 | ||
| 0.211 | 0.019 | 0.211 | Aminopeptidase B inhibitor | 0.211 0.019 DBMET03256 0.211 0.019 DBMET03257 | ||
| 0.234 | 0.045 | 0.234 | Nitric-oxide synthase stimulant | 0.234 0.045 DBMET03256 0.234 0.045 DBMET03257 | ||
| 0.199 | 0.011 | 0.199 | Creatine kinase inhibitor | 0.199 0.011 DBMET03256 0.199 0.011 DBMET03257 | ||
| 0.209 | 0.02 | 0.209 | Ferrochelatase inhibitor | 0.209 0.02 DBMET03256 0.209 0.02 DBMET03257 | ||
| 0.221 | 0.033 | 0.221 | Thiol protease inhibitor | 0.221 0.033 DBMET03256 0.221 0.033 DBMET03257 | ||
| 0.211 | 0.024 | 0.211 | Adenylate cyclase inhibitor | 0.211 0.024 DBMET03256 0.211 0.024 DBMET03257 | ||
| 0.193 | 0.008 | 0.193 | Carbamoyl phosphate synthetase inhibitor | 0.193 0.008 DBMET03256 0.193 0.008 DBMET03257 | ||
| 0.212 | 0.029 | 0.212 | Neurotensin receptor agonist | 0.212 0.029 DBMET03256 0.212 0.029 DBMET03257 | ||
| 0.216 | 0.035 | 0.216 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.216 0.035 DBMET03256 0.216 0.035 DBMET03257 | ||
| 0.191 | 0.011 | 0.191 | Caspase 3 inhibitor | 0.191 0.011 DBMET03256 0.191 0.011 DBMET03257 | ||
| 0.2 | 0.024 | 0.2 | Nav1.3 sodium channel blocker | 0.2 0.024 DBMET03256 0.2 0.024 DBMET03257 | ||
| 0.191 | 0.016 | 0.191 | Adenylate kinase inhibitor | 0.191 0.016 DBMET03256 0.191 0.016 DBMET03257 | ||
| 0.182 | 0.008 | 0.182 | Toll-Like receptor 2 agonist | 0.182 0.008 DBMET03256 0.182 0.008 DBMET03257 | ||
| 0.338 | 0.165 | 0.338 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.338 0.165 DBMET03256 0.338 0.165 DBMET03257 | ||
| 0.197 | 0.025 | 0.197 | Antiadrenergic | 0.197 0.025 DBMET03256 0.197 0.025 DBMET03257 | ||
| 0.193 | 0.025 | 0.193 | Adrenaline antagonist | 0.193 0.025 DBMET03256 0.193 0.025 DBMET03257 | ||
| 0.191 | 0.025 | 0.191 | Cathepsin H inhibitor | 0.191 0.025 DBMET03256 0.191 0.025 DBMET03257 | ||
| 0.178 | 0.013 | 0.178 | Prolactin inhibitor | 0.178 0.013 DBMET03256 0.178 0.013 DBMET03257 | ||
| 0.174 | 0.009 | 0.174 | Aminopeptidase I inhibitor | 0.174 0.009 DBMET03256 0.174 0.009 DBMET03257 | ||
| 0.199 | 0.036 | 0.199 | Bone formation stimulant | 0.199 0.036 DBMET03256 0.199 0.036 DBMET03257 | ||
| 0.173 | 0.013 | 0.173 | GABA C receptor rho-1 antagonist | 0.173 0.013 DBMET03256 0.173 0.013 DBMET03257 | ||
| 0.171 | 0.012 | 0.171 | Ca2+-transporting ATPase inhibitor | 0.171 0.012 DBMET03256 0.171 0.012 DBMET03257 | ||
| 0.171 | 0.013 | 0.171 | Hematopoietic | 0.171 0.013 DBMET03256 0.171 0.013 DBMET03257 | ||
| 0.195 | 0.037 | 0.195 | Arachidonic acid antagonist | 0.195 0.037 DBMET03256 0.195 0.037 DBMET03257 | ||
| 0.208 | 0.05 | 0.208 | 5 Hydroxytryptamine 3E antagonist | 0.208 0.05 DBMET03256 0.208 0.05 DBMET03257 | ||
| 0.172 | 0.015 | 0.172 | Triose-phosphate isomerase inhibitor | 0.172 0.015 DBMET03256 0.172 0.015 DBMET03257 | ||
| 0.185 | 0.03 | 0.185 | Proteasome inhibitor | 0.185 0.03 DBMET03256 0.185 0.03 DBMET03257 | ||
| 0.18 | 0.028 | 0.18 | Chelator | 0.18 0.028 DBMET03256 0.18 0.028 DBMET03257 | ||
| 0.191 | 0.041 | 0.191 | CDC-like kinase 1 inhibitor | 0.191 0.041 DBMET03256 0.191 0.041 DBMET03257 | ||
| 0.165 | 0.015 | 0.165 | Phosphofructokinase-1 inhibitor | 0.165 0.015 DBMET03256 0.165 0.015 DBMET03257 | ||
| 0.159 | 0.01 | 0.159 | Phenylalanine 4-hydroxylase inhibitor | 0.159 0.01 DBMET03256 0.159 0.01 DBMET03257 | ||
| 0.159 | 0.011 | 0.159 | Argininosuccinate synthase inhibitor | 0.159 0.011 DBMET03256 0.159 0.011 DBMET03257 | ||
| 0.157 | 0.008 | 0.157 | Acyl-CoA dehydrogenase inhibitor | 0.157 0.008 DBMET03256 0.157 0.008 DBMET03257 | ||
| 0.179 | 0.031 | 0.179 | Neuropeptide Y1 antagonist | 0.179 0.031 DBMET03256 0.179 0.031 DBMET03257 | ||
| 0.21 | 0.064 | 0.21 | Insulin sensitizer | 0.21 0.064 DBMET03256 0.21 0.064 DBMET03257 | ||
| 0.184 | 0.039 | 0.184 | GABA C receptor rho-2 antagonist | 0.184 0.039 DBMET03256 0.184 0.039 DBMET03257 | ||
| 0.163 | 0.018 | 0.163 | Nitric-oxide synthase inhibitor | 0.163 0.018 DBMET03256 0.163 0.018 DBMET03257 | ||
| 0.167 | 0.023 | 0.167 | Sphingosine 1-phosphate receptor 2 antagonist | 0.167 0.023 DBMET03256 0.167 0.023 DBMET03257 | ||
| 0.15 | 0.011 | 0.15 | Ornithine decarboxylase inhibitor | 0.15 0.011 DBMET03256 0.15 0.011 DBMET03257 | ||
| 0.144 | 0.006 | 0.144 | Beta adrenoreceptor antagonist | 0.144 0.006 DBMET03256 0.144 0.006 DBMET03257 | ||
| 0.161 | 0.025 | 0.161 | UDP-glucose 4-epimerase inhibitor | 0.161 0.025 DBMET03256 0.161 0.025 DBMET03257 | ||
| 0.162 | 0.026 | 0.162 | Mucolytic | 0.162 0.026 DBMET03256 0.162 0.026 DBMET03257 | ||
| 0.179 | 0.043 | 0.179 | Hemostatic | 0.179 0.043 DBMET03256 0.179 0.043 DBMET03257 | ||
| 0.257 | 0.122 | 0.257 | Transcription factor NF kappa B inhibitor | 0.257 0.122 DBMET03256 0.257 0.122 DBMET03257 | ||
| 0.149 | 0.016 | 0.149 | Glutamate dehydrogenase inhibitor | 0.149 0.016 DBMET03256 0.149 0.016 DBMET03257 | ||
| 0.146 | 0.014 | 0.146 | Glutamate decarboxylase inhibitor | 0.146 0.014 DBMET03256 0.146 0.014 DBMET03257 | ||
| 0.134 | 0.004 | 0.134 | Phospholipase D inhibitor | 0.134 0.004 DBMET03256 0.134 0.004 DBMET03257 | ||
| 0.167 | 0.038 | 0.167 | Sphingosine 1-phosphate receptor 5 antagonist | 0.167 0.038 DBMET03256 0.167 0.038 DBMET03257 | ||
| 0.23 | 0.101 | 0.23 | Transcription factor STAT3 inhibitor | 0.23 0.101 DBMET03256 0.23 0.101 DBMET03257 | ||
| 0.147 | 0.018 | 0.147 | NADH dehydrogenase inhibitor | 0.147 0.018 DBMET03256 0.147 0.018 DBMET03257 | ||
| 0.139 | 0.012 | 0.139 | Interferon agonist | 0.139 0.012 DBMET03256 0.139 0.012 DBMET03257 | ||
| 0.146 | 0.018 | 0.146 | MAP kinase kinase 1 inhibitor | 0.146 0.018 DBMET03256 0.146 0.018 DBMET03257 | ||
| 0.158 | 0.031 | 0.158 | Vanilloid 1 agonist | 0.158 0.031 DBMET03256 0.158 0.031 DBMET03257 | ||
| 0.136 | 0.01 | 0.136 | NMDA receptor agonist | 0.136 0.01 DBMET03256 0.136 0.01 DBMET03257 | ||
| 0.221 | 0.095 | 0.221 | Hypoglycemic | 0.221 0.095 DBMET03256 0.221 0.095 DBMET03257 | ||
| 0.264 | 0.138 | 0.264 | Immunosuppressant | 0.264 0.138 DBMET03256 0.264 0.138 DBMET03257 | ||
| 0.138 | 0.013 | 0.138 | Ribonucleoside-diphosphate reductase inhibitor | 0.138 0.013 DBMET03256 0.138 0.013 DBMET03257 | ||
| 0.13 | 0.005 | 0.13 | Myc inhibitor | 0.13 0.005 DBMET03256 0.13 0.005 DBMET03257 | ||
| 0.171 | 0.046 | 0.171 | Nav1.2 sodium channel blocker | 0.171 0.046 DBMET03256 0.171 0.046 DBMET03257 | ||
| 0.136 | 0.014 | 0.136 | Ribonucleotide reductase inhibitor | 0.136 0.014 DBMET03256 0.136 0.014 DBMET03257 | ||
| 0.131 | 0.01 | 0.131 | Glycine receptor agonist | 0.131 0.01 DBMET03256 0.131 0.01 DBMET03257 | ||
| 0.212 | 0.091 | 0.212 | Antiamyloidogenic | 0.212 0.091 DBMET03256 0.212 0.091 DBMET03257 | ||
| 0.15 | 0.03 | 0.15 | Protease inhibitor | 0.15 0.03 DBMET03256 0.15 0.03 DBMET03257 | ||
| 0.213 | 0.093 | 0.213 | Platelet antagonist | 0.213 0.093 DBMET03256 0.213 0.093 DBMET03257 | ||
| 0.15 | 0.031 | 0.15 | Bronchodilator | 0.15 0.031 DBMET03256 0.15 0.031 DBMET03257 | ||
| 0.163 | 0.045 | 0.163 | MAP kinase kinase inhibitor | 0.163 0.045 DBMET03256 0.163 0.045 DBMET03257 | ||
| 0.126 | 0.009 | 0.126 | Beta 3 adrenoreceptor antagonist | 0.126 0.009 DBMET03256 0.126 0.009 DBMET03257 | ||
| 0.146 | 0.033 | 0.146 | Photosensitizer | 0.146 0.033 DBMET03256 0.146 0.033 DBMET03257 | ||
| 0.256 | 0.143 | 0.256 | Toll-Like receptor 7 agonist | 0.256 0.143 DBMET03256 0.256 0.143 DBMET03257 | ||
| 0.121 | 0.009 | 0.121 | Estrogen-related receptor beta agonist | 0.121 0.009 DBMET03256 0.121 0.009 DBMET03257 | ||
| 0.155 | 0.044 | 0.155 | Alkylator | 0.155 0.044 DBMET03256 0.155 0.044 DBMET03257 | ||
| 0.156 | 0.047 | 0.156 | Nav1.6 sodium channel blocker | 0.156 0.047 DBMET03256 0.156 0.047 DBMET03257 | ||
| 0.168 | 0.06 | 0.168 | Acetylcholine M1 receptor antagonist | 0.168 0.06 DBMET03256 0.168 0.06 DBMET03257 | ||
| 0.203 | 0.095 | 0.203 | RNA-directed DNA polymerase inhibitor | 0.203 0.095 DBMET03256 0.203 0.095 DBMET03257 | ||
| 0.115 | 0.006 | 0.115 | Beta 2 adrenoreceptor antagonist | 0.115 0.006 DBMET03256 0.115 0.006 DBMET03257 | ||
| 0.12 | 0.012 | 0.12 | Neuraminidase (influenza) inhibitor | 0.12 0.012 DBMET03256 0.12 0.012 DBMET03257 | ||
| 0.116 | 0.008 | 0.116 | Vanilloid 4 agonist | 0.116 0.008 DBMET03256 0.116 0.008 DBMET03257 | ||
| 0.161 | 0.053 | 0.161 | Histone deacetylase SIRT1 inhibitor | 0.161 0.053 DBMET03256 0.161 0.053 DBMET03257 | ||
| 0.121 | 0.015 | 0.121 | Granulocyte macrophage colony stimulating factor agonist | 0.121 0.015 DBMET03256 0.121 0.015 DBMET03257 | ||
| 0.114 | 0.008 | 0.114 | Beta 1 adrenoreceptor antagonist | 0.114 0.008 DBMET03256 0.114 0.008 DBMET03257 | ||
| 0.109 | 0.005 | 0.109 | Alpha-mannosidase inhibitor | 0.109 0.005 DBMET03256 0.109 0.005 DBMET03257 | ||
| 0.132 | 0.029 | 0.132 | Anabolic | 0.132 0.029 DBMET03256 0.132 0.029 DBMET03257 | ||
| 0.134 | 0.032 | 0.134 | DOPA decarboxylase inhibitor | 0.134 0.032 DBMET03256 0.134 0.032 DBMET03257 | ||
| 0.15 | 0.048 | 0.15 | Cyclooxygenase 3 inhibitor | 0.15 0.048 DBMET03256 0.15 0.048 DBMET03257 | ||
| 0.111 | 0.009 | 0.111 | Interferon inducer | 0.111 0.009 DBMET03256 0.111 0.009 DBMET03257 | ||
| 0.112 | 0.012 | 0.112 | Neuraminidase inhibitor | 0.112 0.012 DBMET03256 0.112 0.012 DBMET03257 | ||
| 0.122 | 0.022 | 0.122 | Glutathione S-transferase inhibitor | 0.122 0.022 DBMET03256 0.122 0.022 DBMET03257 | ||
| 0.131 | 0.034 | 0.131 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.131 0.034 DBMET03256 0.131 0.034 DBMET03257 | ||
| 0.275 | 0.18 | 0.275 | Calcium channel L-type activator | 0.275 0.18 DBMET03256 0.275 0.18 DBMET03257 | ||
| 0.102 | 0.008 | 0.102 | Glucosylceramidase inhibitor | 0.102 0.008 DBMET03256 0.102 0.008 DBMET03257 | ||
| 0.131 | 0.037 | 0.131 | MAP kinase 8 inhibitor | 0.131 0.037 DBMET03256 0.131 0.037 DBMET03257 | ||
| 0.101 | 0.007 | 0.101 | Sphingosine kinase inhibitor | 0.101 0.007 DBMET03256 0.101 0.007 DBMET03257 | ||
| 0.213 | 0.12 | 0.213 | Transcription factor STAT inhibitor | 0.213 0.12 DBMET03256 0.213 0.12 DBMET03257 | ||
| 0.132 | 0.039 | 0.132 | Sphingosine 1-phosphate receptor 2 agonist | 0.132 0.039 DBMET03256 0.132 0.039 DBMET03257 | ||
| 0.1 | 0.008 | 0.1 | Sphingosine kinase 2 inhibitor | 0.1 0.008 DBMET03256 0.1 0.008 DBMET03257 | ||
| 0.135 | 0.044 | 0.135 | Falcipain 3 inhibitor | 0.135 0.044 DBMET03256 0.135 0.044 DBMET03257 | ||
| 0.125 | 0.034 | 0.125 | Factor V inhibitor | 0.125 0.034 DBMET03256 0.125 0.034 DBMET03257 | ||
| 0.279 | 0.188 | 0.279 | Apoptosis agonist | 0.279 0.188 DBMET03256 0.279 0.188 DBMET03257 | ||
| 0.133 | 0.043 | 0.133 | Expectorant | 0.133 0.043 DBMET03256 0.133 0.043 DBMET03257 | ||
| 0.096 | 0.008 | 0.096 | 5 Hydroxytryptamine 1B agonist | 0.096 0.008 DBMET03256 0.096 0.008 DBMET03257 | ||
| 0.115 | 0.027 | 0.115 | Inducible nitric-oxide synthase inhibitor | 0.115 0.027 DBMET03256 0.115 0.027 DBMET03257 | ||
| 0.091 | 0.004 | 0.091 | Neuraminidase (Influenza A) inhibitor | 0.091 0.004 DBMET03256 0.091 0.004 DBMET03257 | ||
| 0.123 | 0.037 | 0.123 | Folate antagonist | 0.123 0.037 DBMET03256 0.123 0.037 DBMET03257 | ||
| 0.093 | 0.006 | 0.093 | Mannosidase inhibitor | 0.093 0.006 DBMET03256 0.093 0.006 DBMET03257 | ||
| 0.141 | 0.055 | 0.141 | Antibacterial (Helicobacter pylori) | 0.141 0.055 DBMET03256 0.141 0.055 DBMET03257 | ||
| 0.09 | 0.005 | 0.09 | Beta 2 adrenoreceptor agonist | 0.09 0.005 DBMET03256 0.09 0.005 DBMET03257 | ||
| 0.109 | 0.025 | 0.109 | Selectin antagonist | 0.109 0.025 DBMET03256 0.109 0.025 DBMET03257 | ||
| 0.098 | 0.014 | 0.098 | MAP kinase kinase 7 inhibitor | 0.098 0.014 DBMET03256 0.098 0.014 DBMET03257 | ||
| 0.104 | 0.02 | 0.104 | MAP kinase kinase 8 inhibitor | 0.104 0.02 DBMET03256 0.104 0.02 DBMET03257 | ||
| 0.108 | 0.025 | 0.108 | Neuropeptide agonist | 0.108 0.025 DBMET03256 0.108 0.025 DBMET03257 | ||
| 0.108 | 0.026 | 0.108 | Vanilloid agonist | 0.108 0.026 DBMET03256 0.108 0.026 DBMET03257 | ||
| 0.086 | 0.004 | 0.086 | Geranyltranstransferase inhibitor | 0.086 0.004 DBMET03256 0.086 0.004 DBMET03257 | ||
| 0.137 | 0.056 | 0.137 | Aldehyde dehydrogenase inhibitor | 0.137 0.056 DBMET03256 0.137 0.056 DBMET03257 | ||
| 0.094 | 0.013 | 0.094 | Glutamate (mGluR6) antagonist | 0.094 0.013 DBMET03256 0.094 0.013 DBMET03257 | ||
| 0.103 | 0.024 | 0.103 | Sphingosine 1-phosphate receptor 4 agonist | 0.103 0.024 DBMET03256 0.103 0.024 DBMET03257 | ||
| 0.144 | 0.065 | 0.144 | Neurotrophic factor | 0.144 0.065 DBMET03256 0.144 0.065 DBMET03257 | ||
| 0.123 | 0.044 | 0.123 | Carbonic anhydrase XV inhibitor | 0.123 0.044 DBMET03256 0.123 0.044 DBMET03257 | ||
| 0.088 | 0.01 | 0.088 | Nicotinic alpha3beta2 receptor antagonist | 0.088 0.01 DBMET03256 0.088 0.01 DBMET03257 | ||
| 0.094 | 0.018 | 0.094 | Protease 3C (Human rhinovirus) inhibitor | 0.094 0.018 DBMET03256 0.094 0.018 DBMET03257 | ||
| 0.11 | 0.034 | 0.11 | Acetylcholine nicotinic antagonist | 0.11 0.034 DBMET03256 0.11 0.034 DBMET03257 | ||
| 0.087 | 0.012 | 0.087 | Corticotropin releasing factor 2 receptor antagonist | 0.087 0.012 DBMET03256 0.087 0.012 DBMET03257 | ||
| 0.094 | 0.019 | 0.094 | Cathepsin B inhibitor | 0.094 0.019 DBMET03256 0.094 0.019 DBMET03257 | ||
| 0.113 | 0.038 | 0.113 | Glutamate (mGluR7) agonist | 0.113 0.038 DBMET03256 0.113 0.038 DBMET03257 | ||
| 0.142 | 0.067 | 0.142 | Heat shock protein 70 antagonist | 0.142 0.067 DBMET03256 0.142 0.067 DBMET03257 | ||
| 0.078 | 0.005 | 0.078 | Beta adrenoreceptor agonist | 0.078 0.005 DBMET03256 0.078 0.005 DBMET03257 | ||
| 0.151 | 0.077 | 0.151 | Diuretic | 0.151 0.077 DBMET03256 0.151 0.077 DBMET03257 | ||
| 0.103 | 0.031 | 0.103 | Metalloproteinase-9 inhibitor | 0.103 0.031 DBMET03256 0.103 0.031 DBMET03257 | ||
| 0.111 | 0.04 | 0.111 | Lanosterol 14 alpha demethylase inhibitor | 0.111 0.04 DBMET03256 0.111 0.04 DBMET03257 | ||
| 0.094 | 0.022 | 0.094 | Cannabinoid CB1 receptor agonist | 0.094 0.022 DBMET03256 0.094 0.022 DBMET03257 | ||
| 0.193 | 0.121 | 0.193 | DNA damaging | 0.193 0.121 DBMET03256 0.193 0.121 DBMET03257 | ||
| 0.079 | 0.009 | 0.079 | Glucose-6-phosphate isomerase inhibitor | 0.079 0.009 DBMET03256 0.079 0.009 DBMET03257 | ||
| 0.173 | 0.103 | 0.173 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.173 0.103 DBMET03256 0.173 0.103 DBMET03257 | ||
| 0.102 | 0.033 | 0.102 | Histamine H2 receptor antagonist | 0.102 0.033 DBMET03256 0.102 0.033 DBMET03257 | ||
| 0.174 | 0.105 | 0.174 | Neurotrophic factor enhancer | 0.174 0.105 DBMET03256 0.174 0.105 DBMET03257 | ||
| 0.091 | 0.022 | 0.091 | Cathepsin L inhibitor | 0.091 0.022 DBMET03256 0.091 0.022 DBMET03257 | ||
| 0.116 | 0.047 | 0.116 | Carbonic anhydrase III inhibitor | 0.116 0.047 DBMET03256 0.116 0.047 DBMET03257 | ||
| 0.084 | 0.016 | 0.084 | Cyclin H inhibitor | 0.084 0.016 DBMET03256 0.084 0.016 DBMET03257 | ||
| 0.15 | 0.081 | 0.15 | Melanin inhibitor | 0.15 0.081 DBMET03256 0.15 0.081 DBMET03257 | ||
| 0.1 | 0.032 | 0.1 | Na+ K+ transporting ATPase inhibitor | 0.1 0.032 DBMET03256 0.1 0.032 DBMET03257 | ||
| 0.094 | 0.025 | 0.094 | Glucagon-like peptide 1 agonist | 0.094 0.025 DBMET03256 0.094 0.025 DBMET03257 | ||
| 0.104 | 0.037 | 0.104 | Glutamate release inhibitor | 0.104 0.037 DBMET03256 0.104 0.037 DBMET03257 | ||
| 0.111 | 0.044 | 0.111 | Electrolyte absorption antagonist | 0.111 0.044 DBMET03256 0.111 0.044 DBMET03257 | ||
| 0.077 | 0.011 | 0.077 | Lysophosphatidic acid 3 receptor antagonist | 0.077 0.011 DBMET03256 0.077 0.011 DBMET03257 | ||
| 0.073 | 0.007 | 0.073 | Arginase inhibitor | 0.073 0.007 DBMET03256 0.073 0.007 DBMET03257 | ||
| 0.071 | 0.006 | 0.071 | Sphingosine kinase 1 inhibitor | 0.071 0.006 DBMET03256 0.071 0.006 DBMET03257 | ||
| 0.147 | 0.082 | 0.147 | Interferon gamma antagonist | 0.147 0.082 DBMET03256 0.147 0.082 DBMET03257 | ||
| 0.12 | 0.055 | 0.12 | CDK3/cyclin E inhibitor | 0.12 0.055 DBMET03256 0.12 0.055 DBMET03257 | ||
| 0.066 | 0.003 | 0.066 | Lysophosphatidic acid receptor 1 agonist | 0.066 0.003 DBMET03256 0.066 0.003 DBMET03257 | ||
| 0.136 | 0.072 | 0.136 | Aurora-C kinase inhibitor | 0.136 0.072 DBMET03256 0.136 0.072 DBMET03257 | ||
| 0.129 | 0.066 | 0.129 | Cholinergic antagonist | 0.129 0.066 DBMET03256 0.129 0.066 DBMET03257 | ||
| 0.101 | 0.038 | 0.101 | Transcription factor NF kappa B stimulant | 0.101 0.038 DBMET03256 0.101 0.038 DBMET03257 | ||
| 0.1 | 0.038 | 0.1 | Metalloproteinase-2 inhibitor | 0.1 0.038 DBMET03256 0.1 0.038 DBMET03257 | ||
| 0.12 | 0.058 | 0.12 | Alpha 2b adrenoreceptor antagonist | 0.12 0.058 DBMET03256 0.12 0.058 DBMET03257 | ||
| 0.069 | 0.01 | 0.069 | Oxytocin agonist | 0.069 0.01 DBMET03256 0.069 0.01 DBMET03257 | ||
| 0.097 | 0.037 | 0.097 | Porphobilinogen synthase inhibitor | 0.097 0.037 DBMET03256 0.097 0.037 DBMET03257 | ||
| 0.137 | 0.078 | 0.137 | Protein kinase stimulant | 0.137 0.078 DBMET03256 0.137 0.078 DBMET03257 | ||
| 0.09 | 0.031 | 0.09 | Matrix metalloproteinase inhibitor | 0.09 0.031 DBMET03256 0.09 0.031 DBMET03257 | ||
| 0.064 | 0.005 | 0.064 | Lysine carboxypeptidase inhibitor | 0.064 0.005 DBMET03256 0.064 0.005 DBMET03257 | ||
| 0.124 | 0.065 | 0.124 | Sphingosine 1-phosphate receptor 4 antagonist | 0.124 0.065 DBMET03256 0.124 0.065 DBMET03257 | ||
| 0.074 | 0.015 | 0.074 | Epithelial sodium channel blocker | 0.074 0.015 DBMET03256 0.074 0.015 DBMET03257 | ||
| 0.088 | 0.029 | 0.088 | GABA B receptor agonist | 0.088 0.029 DBMET03256 0.088 0.029 DBMET03257 | ||
| 0.079 | 0.021 | 0.079 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.079 0.021 DBMET03256 0.079 0.021 DBMET03257 | ||
| 0.119 | 0.062 | 0.119 | Microtubule formation inhibitor | 0.119 0.062 DBMET03256 0.119 0.062 DBMET03257 | ||
| 0.229 | 0.172 | 0.229 | Calcium channel activator | 0.229 0.172 DBMET03256 0.229 0.172 DBMET03257 | ||
| 0.092 | 0.035 | 0.092 | Histidine decarboxylase inhibitor | 0.092 0.035 DBMET03256 0.092 0.035 DBMET03257 | ||
| 0.124 | 0.067 | 0.124 | Acetylcholine antagonist | 0.124 0.067 DBMET03256 0.124 0.067 DBMET03257 | ||
| 0.12 | 0.063 | 0.12 | Calcium channel N-type blocker | 0.12 0.063 DBMET03256 0.12 0.063 DBMET03257 | ||
| 0.102 | 0.046 | 0.102 | Calcium antagonist | 0.102 0.046 DBMET03256 0.102 0.046 DBMET03257 | ||
| 0.065 | 0.01 | 0.065 | Factor XIIIa inhibitor | 0.065 0.01 DBMET03256 0.065 0.01 DBMET03257 | ||
| 0.128 | 0.075 | 0.128 | Interleukin 4 antagonist | 0.128 0.075 DBMET03256 0.128 0.075 DBMET03257 | ||
| 0.082 | 0.03 | 0.082 | Neutrophil collagenase inhibitor | 0.082 0.03 DBMET03256 0.082 0.03 DBMET03257 | ||
| 0.059 | 0.007 | 0.059 | Lysophosphatidic acid 2 receptor antagonist | 0.059 0.007 DBMET03256 0.059 0.007 DBMET03257 | ||
| 0.084 | 0.032 | 0.084 | Secretase beta inhibitor | 0.084 0.032 DBMET03256 0.084 0.032 DBMET03257 | ||
| 0.088 | 0.037 | 0.088 | GABA aminotransferase inhibitor | 0.088 0.037 DBMET03256 0.088 0.037 DBMET03257 | ||
| 0.092 | 0.04 | 0.092 | MAP kinase 10 inhibitor | 0.092 0.04 DBMET03256 0.092 0.04 DBMET03257 | ||
| 0.214 | 0.163 | 0.214 | Apoptosis antagonist | 0.214 0.163 DBMET03256 0.214 0.163 DBMET03257 | ||
| 0.092 | 0.042 | 0.092 | Chymotrypsin inhibitor | 0.092 0.042 DBMET03256 0.092 0.042 DBMET03257 | ||
| 0.07 | 0.021 | 0.07 | Glycine transporter 2 inhibitor | 0.07 0.021 DBMET03256 0.07 0.021 DBMET03257 | ||
| 0.103 | 0.054 | 0.103 | Interleukin 1 beta converting enzyme inhibitor | 0.103 0.054 DBMET03256 0.103 0.054 DBMET03257 | ||
| 0.078 | 0.03 | 0.078 | NMDA receptor glycine site agonist | 0.078 0.03 DBMET03256 0.078 0.03 DBMET03257 | ||
| 0.127 | 0.08 | 0.127 | Calcium channel blocker | 0.127 0.08 DBMET03256 0.127 0.08 DBMET03257 | ||
| 0.089 | 0.044 | 0.089 | Glycine receptor antagonist | 0.089 0.044 DBMET03256 0.089 0.044 DBMET03257 | ||
| 0.063 | 0.018 | 0.063 | Adenosine deaminase inhibitor | 0.063 0.018 DBMET03256 0.063 0.018 DBMET03257 | ||
| 0.059 | 0.014 | 0.059 | Sphingosine 1-phosphate receptor 1 agonist | 0.059 0.014 DBMET03256 0.059 0.014 DBMET03257 | ||
| 0.057 | 0.012 | 0.057 | Membrane dipeptidase inhibitor | 0.057 0.012 DBMET03256 0.057 0.012 DBMET03257 | ||
| 0.149 | 0.105 | 0.149 | DNA methyltransferase I inhibitor | 0.149 0.105 DBMET03256 0.149 0.105 DBMET03257 | ||
| 0.14 | 0.096 | 0.14 | CF transmembrane conductance regulator agonist | 0.14 0.096 DBMET03256 0.14 0.096 DBMET03257 | ||
| 0.08 | 0.036 | 0.08 | Potassium channel (Tandem pore domain) blocker | 0.08 0.036 DBMET03256 0.08 0.036 DBMET03257 | ||
| 0.085 | 0.041 | 0.085 | Cathepsin G inhibitor | 0.085 0.041 DBMET03256 0.085 0.041 DBMET03257 | ||
| 0.054 | 0.01 | 0.054 | Kainate receptor agonist | 0.054 0.01 DBMET03256 0.054 0.01 DBMET03257 | ||
| 0.069 | 0.026 | 0.069 | Gonadotropin-releasing hormone receptor agonist | 0.069 0.026 DBMET03256 0.069 0.026 DBMET03257 | ||
| 0.066 | 0.023 | 0.066 | Antimetabolite | 0.066 0.023 DBMET03256 0.066 0.023 DBMET03257 | ||
| 0.059 | 0.017 | 0.059 | Sphingosine 1-phosphate receptor agonist | 0.059 0.017 DBMET03256 0.059 0.017 DBMET03257 | ||
| 0.047 | 0.004 | 0.047 | Purinergic P2Y15 antagonist | 0.047 0.004 DBMET03256 0.047 0.004 DBMET03257 | ||
| 0.05 | 0.007 | 0.05 | Ceramide glucosyltransferase inhibitor | 0.05 0.007 DBMET03256 0.05 0.007 DBMET03257 | ||
| 0.062 | 0.02 | 0.062 | Immunoglobulin Fc receptor antagonist | 0.062 0.02 DBMET03256 0.062 0.02 DBMET03257 | ||
| 0.072 | 0.03 | 0.072 | Nitric oxide donor | 0.072 0.03 DBMET03256 0.072 0.03 DBMET03257 | ||
| 0.072 | 0.03 | 0.072 | Carbonic anhydrase stimulant | 0.072 0.03 DBMET03256 0.072 0.03 DBMET03257 | ||
| 0.105 | 0.064 | 0.105 | Mediator release inhibitor | 0.105 0.064 DBMET03256 0.105 0.064 DBMET03257 | ||
| 0.044 | 0.004 | 0.044 | Acid ceramidase inhibitor | 0.044 0.004 DBMET03256 0.044 0.004 DBMET03257 | ||
| 0.05 | 0.009 | 0.05 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.05 0.009 DBMET03256 0.05 0.009 DBMET03257 | ||
| 0.043 | 0.003 | 0.043 | Lysophosphatidic acid receptor 3 agonist | 0.043 0.003 DBMET03256 0.043 0.003 DBMET03257 | ||
| 0.062 | 0.023 | 0.062 | Bombesin 2 receptor antagonist | 0.062 0.023 DBMET03256 0.062 0.023 DBMET03257 | ||
| 0.064 | 0.024 | 0.064 | Sphingosine 1-phosphate receptor 1 antagonist | 0.064 0.024 DBMET03256 0.064 0.024 DBMET03257 | ||
| 0.093 | 0.054 | 0.093 | Ca(v)2.2 blocker | 0.093 0.054 DBMET03256 0.093 0.054 DBMET03257 | ||
| 0.061 | 0.023 | 0.061 | Metalloproteinase-3 inhibitor | 0.061 0.023 DBMET03256 0.061 0.023 DBMET03257 | ||
| 0.067 | 0.03 | 0.067 | Human rhinovirus A protease inhibitor | 0.067 0.03 DBMET03256 0.067 0.03 DBMET03257 | ||
| 0.059 | 0.022 | 0.059 | HCV NS3/NS4A protease inhibitor | 0.059 0.022 DBMET03256 0.059 0.022 DBMET03257 | ||
| 0.05 | 0.013 | 0.05 | Cathepsin F inhibitor | 0.05 0.013 DBMET03256 0.05 0.013 DBMET03257 | ||
| 0.052 | 0.015 | 0.052 | Kainate receptor 2 antagonist | 0.052 0.015 DBMET03256 0.052 0.015 DBMET03257 | ||
| 0.057 | 0.02 | 0.057 | Macrophage elastase inhibitor | 0.057 0.02 DBMET03256 0.057 0.02 DBMET03257 | ||
| 0.069 | 0.033 | 0.069 | Bombesin 1 receptor agonist | 0.069 0.033 DBMET03256 0.069 0.033 DBMET03257 | ||
| 0.055 | 0.02 | 0.055 | Cytokine production stimulant | 0.055 0.02 DBMET03256 0.055 0.02 DBMET03257 | ||
| 0.056 | 0.021 | 0.056 | Adenylate cyclase 1 inhibitor | 0.056 0.021 DBMET03256 0.056 0.021 DBMET03257 | ||
| 0.038 | 0.003 | 0.038 | Neuraminidase (Influenza B) inhibitor | 0.038 0.003 DBMET03256 0.038 0.003 DBMET03257 | ||
| 0.067 | 0.032 | 0.067 | Histone deacetylase SIRT3 inhibitor | 0.067 0.032 DBMET03256 0.067 0.032 DBMET03257 | ||
| 0.04 | 0.005 | 0.04 | Estrogen-related receptor gamma antagonist | 0.04 0.005 DBMET03256 0.04 0.005 DBMET03257 | ||
| 0.14 | 0.106 | 0.14 | Antipruritic | 0.14 0.106 DBMET03256 0.14 0.106 DBMET03257 | ||
| 0.068 | 0.034 | 0.068 | Biliverdin reductase inhibitor | 0.068 0.034 DBMET03256 0.068 0.034 DBMET03257 | ||
| 0.046 | 0.012 | 0.046 | Peptide deformylase inhibitor | 0.046 0.012 DBMET03256 0.046 0.012 DBMET03257 | ||
| 0.05 | 0.017 | 0.05 | Dopamine D5 agonist | 0.05 0.017 DBMET03256 0.05 0.017 DBMET03257 | ||
| 0.116 | 0.084 | 0.116 | Amylase inhibitor | 0.116 0.084 DBMET03256 0.116 0.084 DBMET03257 | ||
| 0.163 | 0.131 | 0.163 | Cyclic AMP phosphodiesterase inhibitor | 0.163 0.131 DBMET03256 0.163 0.131 DBMET03257 | ||
| 0.036 | 0.004 | 0.036 | Ileal bile acid transport inhibitor | 0.036 0.004 DBMET03256 0.036 0.004 DBMET03257 | ||
| 0.059 | 0.027 | 0.059 | Aconitate hydratase inhibitor | 0.059 0.027 DBMET03256 0.059 0.027 DBMET03257 | ||
| 0.064 | 0.033 | 0.064 | Sphingosine 1-phosphate receptor 3 antagonist | 0.064 0.033 DBMET03256 0.064 0.033 DBMET03257 | ||
| 0.042 | 0.011 | 0.042 | Carboxypeptidase B inhibitor | 0.042 0.011 DBMET03256 0.042 0.011 DBMET03257 | ||
| 0.134 | 0.103 | 0.134 | MAP kinase kinase 4 inhibitor | 0.134 0.103 DBMET03256 0.134 0.103 DBMET03257 | ||
| 0.048 | 0.017 | 0.048 | Calcitonin receptor agonist | 0.048 0.017 DBMET03256 0.048 0.017 DBMET03257 | ||
| 0.047 | 0.017 | 0.047 | AMPA 4 receptor antagonist | 0.047 0.017 DBMET03256 0.047 0.017 DBMET03257 | ||
| 0.051 | 0.021 | 0.051 | Histamine H2 receptor agonist | 0.051 0.021 DBMET03256 0.051 0.021 DBMET03257 | ||
| 0.109 | 0.08 | 0.109 | Acetylcholine muscarinic antagonist | 0.109 0.08 DBMET03256 0.109 0.08 DBMET03257 | ||
| 0.04 | 0.01 | 0.04 | Calcium-independent phospholipase A2 inhibitor | 0.04 0.01 DBMET03256 0.04 0.01 DBMET03257 | ||
| 0.051 | 0.021 | 0.051 | Growth hormone release inhibitor | 0.051 0.021 DBMET03256 0.051 0.021 DBMET03257 | ||
| 0.066 | 0.037 | 0.066 | Calcium channel P-type blocker | 0.066 0.037 DBMET03256 0.066 0.037 DBMET03257 | ||
| 0.105 | 0.076 | 0.105 | Calcium channel (voltage-sensitive) blocker | 0.105 0.076 DBMET03256 0.105 0.076 DBMET03257 | ||
| 0.148 | 0.119 | 0.148 | DNA methylase inhibitor | 0.148 0.119 DBMET03256 0.148 0.119 DBMET03257 | ||
| 0.045 | 0.017 | 0.045 | Potassium channel Kv1.1 blocker | 0.045 0.017 DBMET03256 0.045 0.017 DBMET03257 | ||
| 0.079 | 0.05 | 0.079 | Keratolytic | 0.079 0.05 DBMET03256 0.079 0.05 DBMET03257 | ||
| 0.034 | 0.006 | 0.034 | Beta 1 adrenoreceptor agonist | 0.034 0.006 DBMET03256 0.034 0.006 DBMET03257 | ||
| 0.05 | 0.022 | 0.05 | HIV-1 protease inhibitor | 0.05 0.022 DBMET03256 0.05 0.022 DBMET03257 | ||
| 0.044 | 0.016 | 0.044 | Glutamate (mGluR8) agonist | 0.044 0.016 DBMET03256 0.044 0.016 DBMET03257 | ||
| 0.064 | 0.037 | 0.064 | Plasminogen activator inhibitor | 0.064 0.037 DBMET03256 0.064 0.037 DBMET03257 | ||
| 0.1 | 0.073 | 0.1 | DNA intercalator | 0.1 0.073 DBMET03256 0.1 0.073 DBMET03257 | ||
| 0.045 | 0.018 | 0.045 | Gonadotropin-releasing hormone receptor antagonist | 0.045 0.018 DBMET03256 0.045 0.018 DBMET03257 | ||
| 0.04 | 0.014 | 0.04 | Melatonin receptor 1A agonist | 0.04 0.014 DBMET03256 0.04 0.014 DBMET03257 | ||
| 0.129 | 0.103 | 0.129 | Pregnane X receptor agonist | 0.129 0.103 DBMET03256 0.129 0.103 DBMET03257 | ||
| 0.142 | 0.116 | 0.142 | ATPase inhibitor | 0.142 0.116 DBMET03256 0.142 0.116 DBMET03257 | ||
| 0.104 | 0.079 | 0.104 | Acetylcholine release stimulant | 0.104 0.079 DBMET03256 0.104 0.079 DBMET03257 | ||
| 0.059 | 0.033 | 0.059 | Matrix metalloproteinase (membrane-type) inhibitor | 0.059 0.033 DBMET03256 0.059 0.033 DBMET03257 | ||
| 0.03 | 0.005 | 0.03 | Toll-Like receptor 8 agonist | 0.03 0.005 DBMET03256 0.03 0.005 DBMET03257 | ||
| 0.068 | 0.043 | 0.068 | MAP kinase kinase 10 inhibitor | 0.068 0.043 DBMET03256 0.068 0.043 DBMET03257 | ||
| 0.062 | 0.038 | 0.062 | Cathepsin E inhibitor | 0.062 0.038 DBMET03256 0.062 0.038 DBMET03257 | ||
| 0.046 | 0.022 | 0.046 | Plasmepsin II inhibitor | 0.046 0.022 DBMET03256 0.046 0.022 DBMET03257 | ||
| 0.051 | 0.028 | 0.051 | Bombesin antagonist | 0.051 0.028 DBMET03256 0.051 0.028 DBMET03257 | ||
| 0.1 | 0.077 | 0.1 | Protein kinase C gamma inhibitor | 0.1 0.077 DBMET03256 0.1 0.077 DBMET03257 | ||
| 0.037 | 0.014 | 0.037 | Glutamate (mGluR3) agonist | 0.037 0.014 DBMET03256 0.037 0.014 DBMET03257 | ||
| 0.041 | 0.018 | 0.041 | Fumarate hydratase inhibitor | 0.041 0.018 DBMET03256 0.041 0.018 DBMET03257 | ||
| 0.033 | 0.01 | 0.033 | Myristoyl transferase inhibitor | 0.033 0.01 DBMET03256 0.033 0.01 DBMET03257 | ||
| 0.068 | 0.046 | 0.068 | Neuronal nicotinic receptor antagonist | 0.068 0.046 DBMET03256 0.068 0.046 DBMET03257 | ||
| 0.027 | 0.005 | 0.027 | Estrogen-related receptor gamma agonist | 0.027 0.005 DBMET03256 0.027 0.005 DBMET03257 | ||
| 0.026 | 0.005 | 0.026 | Follicle-stimulating hormone antagonist | 0.026 0.005 DBMET03256 0.026 0.005 DBMET03257 | ||
| 0.025 | 0.005 | 0.025 | Antibiotic Anthracycline-like | 0.025 0.005 DBMET03256 0.025 0.005 DBMET03257 | ||
| 0.035 | 0.014 | 0.035 | Bradykinin B2 receptor agonist | 0.035 0.014 DBMET03256 0.035 0.014 DBMET03257 | ||
| 0.025 | 0.004 | 0.025 | Vitamin D receptor agonist | 0.025 0.004 DBMET03256 0.025 0.004 DBMET03257 | ||
| 0.03 | 0.01 | 0.03 | Vanilloid 2 agonist | 0.03 0.01 DBMET03256 0.03 0.01 DBMET03257 | ||
| 0.043 | 0.023 | 0.043 | Factor VIIa inhibitor | 0.043 0.023 DBMET03256 0.043 0.023 DBMET03257 | ||
| 0.072 | 0.052 | 0.072 | Thrombin inhibitor | 0.072 0.052 DBMET03256 0.072 0.052 DBMET03257 | ||
| 0.047 | 0.028 | 0.047 | Baculoviral IAP repeat-containing protein inhibitor | 0.047 0.028 DBMET03256 0.047 0.028 DBMET03257 | ||
| 0.047 | 0.027 | 0.047 | Parathyroid hormone antagonist | 0.047 0.027 DBMET03256 0.047 0.027 DBMET03257 | ||
| 0.052 | 0.032 | 0.052 | Potassium channel (Inward rectifier) activator | 0.052 0.032 DBMET03256 0.052 0.032 DBMET03257 | ||
| 0.062 | 0.043 | 0.062 | Caspase 9 inhibitor | 0.062 0.043 DBMET03256 0.062 0.043 DBMET03257 | ||
| 0.04 | 0.021 | 0.04 | Sphingosine 1-phosphate receptor 3 agonist | 0.04 0.021 DBMET03256 0.04 0.021 DBMET03257 | ||
| 0.039 | 0.02 | 0.039 | Phosphoglycerate kinase inhibitor | 0.039 0.02 DBMET03256 0.039 0.02 DBMET03257 | ||
| 0.075 | 0.056 | 0.075 | Sphingosine 1-phosphate receptor antagonist | 0.075 0.056 DBMET03256 0.075 0.056 DBMET03257 | ||
| 0.043 | 0.024 | 0.043 | Cathepsin L1 inhibitor | 0.043 0.024 DBMET03256 0.043 0.024 DBMET03257 | ||
| 0.048 | 0.03 | 0.048 | Thymidylate synthase inhibitor | 0.048 0.03 DBMET03256 0.048 0.03 DBMET03257 | ||
| 0.045 | 0.027 | 0.045 | Histamine H1 receptor agonist | 0.045 0.027 DBMET03256 0.045 0.027 DBMET03257 | ||
| 0.049 | 0.031 | 0.049 | Potassium channel (ATP-sensitive) activator | 0.049 0.031 DBMET03256 0.049 0.031 DBMET03257 | ||
| 0.054 | 0.036 | 0.054 | Matrix metalloproteinase 1 inhibitor | 0.054 0.036 DBMET03256 0.054 0.036 DBMET03257 | ||
| 0.055 | 0.037 | 0.055 | Cathepsin D inhibitor | 0.055 0.037 DBMET03256 0.055 0.037 DBMET03257 | ||
| 0.102 | 0.084 | 0.102 | Cholesterol synthesis inhibitor | 0.102 0.084 DBMET03256 0.102 0.084 DBMET03257 | ||
| 0.067 | 0.049 | 0.067 | Sirtuin 1 inhibitor | 0.067 0.049 DBMET03256 0.067 0.049 DBMET03257 | ||
| 0.07 | 0.052 | 0.07 | Calcium channel L-type blocker | 0.07 0.052 DBMET03256 0.07 0.052 DBMET03257 | ||
| 0.055 | 0.038 | 0.055 | Angiotensin-converting enzyme inhibitor | 0.055 0.038 DBMET03256 0.055 0.038 DBMET03257 | ||
| 0.027 | 0.01 | 0.027 | Protease (Human cytomegalovirus) inhibitor | 0.027 0.01 DBMET03256 0.027 0.01 DBMET03257 | ||
| 0.138 | 0.121 | 0.138 | Platelet adhesion inhibitor | 0.138 0.121 DBMET03256 0.138 0.121 DBMET03257 | ||
| 0.031 | 0.014 | 0.031 | Cathepsin K inhibitor | 0.031 0.014 DBMET03256 0.031 0.014 DBMET03257 | ||
| 0.028 | 0.011 | 0.028 | Follicle-stimulating hormone agonist | 0.028 0.011 DBMET03256 0.028 0.011 DBMET03257 | ||
| 0.086 | 0.07 | 0.086 | Alcohol dehydrogenase inhibitor | 0.086 0.07 DBMET03256 0.086 0.07 DBMET03257 | ||
| 0.03 | 0.014 | 0.03 | Antidiuretic hormone agonist | 0.03 0.014 DBMET03256 0.03 0.014 DBMET03257 | ||
| 0.074 | 0.059 | 0.074 | Somatostatin 1 agonist | 0.074 0.059 DBMET03256 0.074 0.059 DBMET03257 | ||
| 0.042 | 0.027 | 0.042 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.042 0.027 DBMET03256 0.042 0.027 DBMET03257 | ||
| 0.025 | 0.01 | 0.025 | Isoleucine-tRNA ligase inhibitor | 0.025 0.01 DBMET03256 0.025 0.01 DBMET03257 | ||
| 0.06 | 0.045 | 0.06 | NMDA 2C receptor antagonist | 0.06 0.045 DBMET03256 0.06 0.045 DBMET03257 | ||
| 0.045 | 0.03 | 0.045 | Nicotinic receptor alpha3 subunit antagonist | 0.045 0.03 DBMET03256 0.045 0.03 DBMET03257 | ||
| 0.062 | 0.047 | 0.062 | Cannabinoid receptor agonist | 0.062 0.047 DBMET03256 0.062 0.047 DBMET03257 | ||
| 0.034 | 0.02 | 0.034 | Calpain 1 inhibitor | 0.034 0.02 DBMET03256 0.034 0.02 DBMET03257 | ||
| 0.035 | 0.021 | 0.035 | HCV polyprotein inhibitor | 0.035 0.021 DBMET03256 0.035 0.021 DBMET03257 | ||
| 0.029 | 0.015 | 0.029 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.029 0.015 DBMET03256 0.029 0.015 DBMET03257 | ||
| 0.032 | 0.019 | 0.032 | Plasmepsin I inhibitor | 0.032 0.019 DBMET03256 0.032 0.019 DBMET03257 | ||
| 0.081 | 0.068 | 0.081 | Opioid antagonist | 0.081 0.068 DBMET03256 0.081 0.068 DBMET03257 | ||
| 0.039 | 0.027 | 0.039 | GABA uptake inhibitor | 0.039 0.027 DBMET03256 0.039 0.027 DBMET03257 | ||
| 0.153 | 0.141 | 0.153 | MAP kinase kinase 5 inhibitor | 0.153 0.141 DBMET03256 0.153 0.141 DBMET03257 | ||
| 0.02 | 0.008 | 0.02 | Adenosine A2 receptor agonist | 0.02 0.008 DBMET03256 0.02 0.008 DBMET03257 | ||
| 0.04 | 0.029 | 0.04 | Thymidine kinase inhibitor | 0.04 0.029 DBMET03256 0.04 0.029 DBMET03257 | ||
| 0.02 | 0.009 | 0.02 | Methylmalonyl-CoA mutase inhibitor | 0.02 0.009 DBMET03256 0.02 0.009 DBMET03257 | ||
| 0.023 | 0.012 | 0.023 | Vasopressin 1 agonist | 0.023 0.012 DBMET03256 0.023 0.012 DBMET03257 | ||
| 0.026 | 0.015 | 0.026 | Glutamate (mGluR1) agonist | 0.026 0.015 DBMET03256 0.026 0.015 DBMET03257 | ||
| 0.029 | 0.018 | 0.029 | Uridine phosphorylase inhibitor | 0.029 0.018 DBMET03256 0.029 0.018 DBMET03257 | ||
| 0.027 | 0.017 | 0.027 | Calcium-sensing receptor agonist | 0.027 0.017 DBMET03256 0.027 0.017 DBMET03257 | ||
| 0.019 | 0.009 | 0.019 | Carbonic anhydrase X inhibitor | 0.019 0.009 DBMET03256 0.019 0.009 DBMET03257 | ||
| 0.019 | 0.009 | 0.019 | Carbonic anhydrase VIII inhibitor | 0.019 0.009 DBMET03256 0.019 0.009 DBMET03257 | ||
| 0.035 | 0.026 | 0.035 | Renin inhibitor | 0.035 0.026 DBMET03256 0.035 0.026 DBMET03257 | ||
| 0.018 | 0.009 | 0.018 | Adenosine A2a receptor agonist | 0.018 0.009 DBMET03256 0.018 0.009 DBMET03257 | ||
| 0.033 | 0.024 | 0.033 | Growth hormone releasing factor agonist | 0.033 0.024 DBMET03256 0.033 0.024 DBMET03257 | ||
| 0.04 | 0.031 | 0.04 | Neurokinin 2 agonist | 0.04 0.031 DBMET03256 0.04 0.031 DBMET03257 | ||
| 0.048 | 0.039 | 0.048 | Squalene epoxidase inhibitor | 0.048 0.039 DBMET03256 0.048 0.039 DBMET03257 | ||
| 0.014 | 0.006 | 0.014 | Beta 3 adrenoreceptor agonist | 0.014 0.006 DBMET03256 0.014 0.006 DBMET03257 | ||
| 0.026 | 0.018 | 0.026 | CXC chemokine 2 receptor antagonist | 0.026 0.018 DBMET03256 0.026 0.018 DBMET03257 | ||
| 0.08 | 0.071 | 0.08 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.08 0.071 DBMET03256 0.08 0.071 DBMET03257 | ||
| 0.074 | 0.066 | 0.074 | Carbonic anhydrase VI inhibitor | 0.074 0.066 DBMET03256 0.074 0.066 DBMET03257 | ||
| 0.022 | 0.014 | 0.022 | Vitamin D receptor antagonist | 0.022 0.014 DBMET03256 0.022 0.014 DBMET03257 | ||
| 0.038 | 0.03 | 0.038 | Dihydropteroate synthase inhibitor | 0.038 0.03 DBMET03256 0.038 0.03 DBMET03257 | ||
| 0.047 | 0.04 | 0.047 | Diacylglycerol O-acyltransferase inhibitor | 0.047 0.04 DBMET03256 0.047 0.04 DBMET03257 | ||
| 0.054 | 0.047 | 0.054 | Botulinum neurotoxin type A inhibitor | 0.054 0.047 DBMET03256 0.054 0.047 DBMET03257 | ||
| 0.06 | 0.053 | 0.06 | Prolactin release inhibitor | 0.06 0.053 DBMET03256 0.06 0.053 DBMET03257 | ||
| 0.013 | 0.007 | 0.013 | Calcium-dependent phospholipase A2 inhibitor | 0.013 0.007 DBMET03256 0.013 0.007 DBMET03257 | ||
| 0.043 | 0.036 | 0.043 | Plasmin inhibitor | 0.043 0.036 DBMET03256 0.043 0.036 DBMET03257 | ||
| 0.054 | 0.048 | 0.054 | Pregnane X receptor antagonist | 0.054 0.048 DBMET03256 0.054 0.048 DBMET03257 | ||
| 0.018 | 0.012 | 0.018 | Aminopeptidase A inhibitor | 0.018 0.012 DBMET03256 0.018 0.012 DBMET03257 | ||
| 0.049 | 0.044 | 0.049 | Dipeptidyl peptidase inhibitor | 0.049 0.044 DBMET03256 0.049 0.044 DBMET03257 | ||
| 0.039 | 0.033 | 0.039 | Complement C3a chemotactic receptor antagonist | 0.039 0.033 DBMET03256 0.039 0.033 DBMET03257 | ||
| 0.017 | 0.012 | 0.017 | Telomerase stimulant | 0.017 0.012 DBMET03256 0.017 0.012 DBMET03257 | ||
| 0.021 | 0.017 | 0.021 | Glutamate (mGluR1a) agonist | 0.021 0.017 DBMET03256 0.021 0.017 DBMET03257 | ||
| 0.027 | 0.023 | 0.027 | Vasopressin 1A agonist | 0.027 0.023 DBMET03256 0.027 0.023 DBMET03257 | ||
| 0.043 | 0.039 | 0.043 | GP IIb/IIIa receptor antagonist | 0.043 0.039 DBMET03256 0.043 0.039 DBMET03257 | ||
| 0.077 | 0.073 | 0.077 | Myeloperoxidase inhibitor | 0.077 0.073 DBMET03256 0.077 0.073 DBMET03257 | ||
| 0.049 | 0.045 | 0.049 | Vanilloid 2 antagonist | 0.049 0.045 DBMET03256 0.049 0.045 DBMET03257 | ||
| 0.054 | 0.051 | 0.054 | Heat shock protein 90 beta antagonist | 0.054 0.051 DBMET03256 0.054 0.051 DBMET03257 | ||
| 0.027 | 0.024 | 0.027 | Trypsin II inhibitor | 0.027 0.024 DBMET03256 0.027 0.024 DBMET03257 | ||
| 0.026 | 0.023 | 0.026 | AMPA 3 receptor antagonist | 0.026 0.023 DBMET03256 0.026 0.023 DBMET03257 | ||
| 0.046 | 0.043 | 0.046 | Prolyl endopeptidase inhibitor | 0.046 0.043 DBMET03256 0.046 0.043 DBMET03257 | ||
| 0.026 | 0.024 | 0.026 | Hedgehog signaling activator | 0.026 0.024 DBMET03256 0.026 0.024 DBMET03257 | ||
| 0.015 | 0.014 | 0.015 | KiSS-1 receptor antagonist | 0.015 0.014 DBMET03256 0.015 0.014 DBMET03257 | ||
| 0.016 | 0.015 | 0.016 | Cyclin T1 inhibitor | 0.016 0.015 DBMET03256 0.016 0.015 DBMET03257 | ||
| 0.04 | 0.039 | 0.04 | Glutamate (mGluR4) antagonist | 0.04 0.039 DBMET03256 0.04 0.039 DBMET03257 | ||
| 0.01 | 0.009 | 0.01 | Carboxypeptidase B2 inhibitor | 0.01 0.009 DBMET03256 0.01 0.009 DBMET03257 | ||
| 0.015 | 0.014 | 0.015 | Vasopressin 2 agonist | 0.015 0.014 DBMET03256 0.015 0.014 DBMET03257 | ||
| 0.053 | 0.052 | 0.053 | Collagenase 3 inhibitor | 0.053 0.052 DBMET03256 0.053 0.052 DBMET03257 | ||
| 0.013 | 0.012 | 0.013 | Integrin alphaVbeta6 antagonist | 0.013 0.012 DBMET03256 0.013 0.012 DBMET03257 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |